Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Raising a heterologous tier 2 neutralizing antibody (nAb) response stays a daunting job for HIV vaccine growth. In this research, we explored the utility of numerous HIV-1 envelope (Env) immunogens in a sequential immunization scheme as a answer to this job. This exploration stemmed from the rationale that gp145, a membrane-bound truncation kind of HIV Env, could facilitate the focusing of induced antibody response on neutralizing epitopes when sequentially mixed with the soluble gp140 kind as immunogens in a prime-boost mode. We first confirmed that gp140 DNA prime-gp145 Tiantan vaccinia (TV) enhance probably represents a common format for inducing potent nAb response in mice.

However, when examined in rhesus macaque, this modality confirmed little effectiveness. To enhance the efficacy, we prolonged the unique modality by including a robust protein enhance, particularly native-like SOSIP.664 trimer displayed on ferritin-based nanoparticle (NP), which was generated by a newly developed click on method. The ensuing three-immunization routine succeeded in eliciting tier-2 nAb response with substantial breadth when carried out in rhesus macaque over a brief 8-week schedule. Importantly, the elicited nAb response was in a position to successfully comprise viremia upon a heterologous SHIV problem. Collectively, our research highlighted that diversification of Env immunogens, in each varieties and formulations, underneath the framework of a sequential immunization scheme would possibly open new alternative towards HIV vaccine growth.

An efficacious HIV-1 vaccine has remained an elusive goal for nearly 40 years. The sheer variety of the virus is one of the most important roadblocks for vaccine growth. HIV-1 often mutates and numerous strains predominate in numerous geographic areas, making the event of a globally relevant vaccine extraordinarily troublesome. Multiple approaches have been taken to overcome the problem of viral variety, together with sequence optimization, growth of consensus and mosaic sequences and the use of totally different prime-boost approaches. To develop an efficacious vaccine, these approaches may have to be mixed. One method to probably synergize these approaches is to use a rationally designed protein nanoparticle that enables for the native-like presentation of antigens, such because the self-assembling protein nanoparticle.

Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates

The seek for a preventive vaccine towards HIV an infection stays an ongoing problem, indicating the necessity for novel approaches. Parainfluenza virus 5 (PIV5) is a paramyxovirus replicating within the higher airways that isn’t related with any animal or human pathology. In animal fashions, PIV5-vectored vaccines have proven safety towards influenza, RSV, and different human pathogens. Here, we generated PIV5 vaccines expressing HIV envelope (Env) and SIV Gag and administered them intranasally to macaques, adopted by boosting with virus-like particles (VLPs) containing trimeric HIV Env. Moreover, we in contrast the immune responses generated by PIV5-SHIV prime/VLPs enhance routine in naïve vs a management group wherein pre-existing immunity to the PIV5 vector was established.

We display for the primary time that intranasal administration of PIV5-based HIV vaccines is protected, well-tolerated and immunogenic, and that boosting with adjuvanted trimeric Env VLPs enhances humoral and mobile immune responses. The PIV5 prime/VLPs enhance routine induced strong and sturdy systemic and mucosal Env-specific antibody titers with practical actions together with ADCC and neutralization. This routine additionally induced extremely polyfunctional antigen-specific T cell responses. Importantly, we present that diminished responses due to PIV5 pre-existing immunity may be overcome partly with VLP protein boosts.

Overall, these outcomes set up that PIV5-based HIV vaccine candidates are promising and warrant additional investigation together with transferring on to primate problem research. This blended strategies research aimed to consider the feasibility and preliminary efficacy of a totally automated, interactive smartphone-delivered intervention for smoking cessation amongst individuals dwelling with HIV in Cambodia. We used the explanatory sequential design, with a pilot two-group single-blind randomized managed trial (N = 50) adopted by in-depth interviews with all trial individuals. In the trial, individuals had been randomized to Standard Care (SC) or Automated Messaging (AM) group. SC comprised temporary recommendation to give up and self-help supplies.

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Exploring HIV stigma amongst future healthcare suppliers in Indonesia

Future healthcare professionals are an vital group for interventions to get rid of HIV stigma within the well being workforce. Researchers examined HIV stigma and its relationship with healthcare self-discipline, HIV information, and religiosity amongst nursing, medical, and midwifery college students (N = 505) in three areas of Indonesia. In a multivariable linear mannequin, larger HIV stigma was related with male intercourse, decrease ranges of earnings and HIV information, and better ranges of religiosity. An interplay of healthcare self-discipline and province was additionally important. Medical college students in Jakarta had larger predicted stigma scores in contrast to nursing college students in Jakarta and in contrast to medical college students in different provinces.

Nursing college students in Papua had decrease predicted stigma scores in contrast to medical and midwifery college students in Papua and in contrast to nursing college students elsewhere. Strategies to cut back HIV stigma within the Indonesian well being workforce ought to embrace a robust deal with pre-clinical academic settings and contemplate public nursing establishments as offering attainable greatest apply fashions. Human immunodeficiency virus sort 1 (HIV-1) is principally transmitted by sexual activity, and efficient microbicides stopping HIV-1 transmission are nonetheless required.

Recombinant HIV-1 Envelope, His Tag

7-07590 1000µg Ask for price

HIV 1 envelope recombinant antigen

00176-V-01mg 0,1 mg
EUR 267.5
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

HIV 1 envelope recombinant antigen

00176-V-1000ug 1000 ug
EUR 1282.5
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

Recombinant HIV-1 Envelope (233)

7-07585 100µg Ask for price

Recombinant HIV-1 Envelope (233)

7-07586 500µg Ask for price

Recombinant HIV-1 Envelope (233)

7-07587 1000µg Ask for price

Recombinant HIV-2 Envelope

7-07744 100µg Ask for price

Recombinant HIV-2 Envelope

7-07745 500µg Ask for price

Recombinant HIV-2 Envelope

7-07746 1000µg Ask for price

HIV 1, 2 envelope recombinant antigen

00175-V-01mg 0,1 mg
EUR 267.5
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

HIV 1, 2 envelope recombinant antigen

00175-V-1000ug 1000 ug
EUR 1282.5
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

Recombinant HIV-1 p24 His Tag

7-07606 5µg Ask for price

Recombinant HIV-1 p24 His Tag

7-07607 20µg Ask for price

Recombinant HIV-1 p24 His Tag

7-07608 1mg Ask for price

Recombinant HIV-1 gp41, His tag

7-07627 100µg Ask for price

Recombinant HIV-1 gp41, His tag

7-07628 500µg Ask for price

Recombinant HIV-1 gp41, His tag

7-07629 1000µg Ask for price

HIV type 1 Envelope protein [His]

DAG1511 100 µg
EUR 645

Recombinant HIV-1 Envelope conjugated to HIV-2 gp39

7-07711 100µg Ask for price

Recombinant HIV-1 Envelope conjugated to HIV-2 gp39

7-07712 500µg Ask for price

Recombinant HIV-1 Envelope conjugated to HIV-2 gp39

7-07713 1000µg Ask for price

Recombinant HIV Type-O Envelope

7-07714 100µg Ask for price

Recombinant HIV Type-O Envelope

7-07715 500µg Ask for price

Recombinant HIV Type-O Envelope

7-07716 1000µg Ask for price

Recombinant (E.Coli) HIV-2 Envelope

RP-573 100 ug
EUR 286

HIV type 1 Envelope protein

DAG1552 100 µg
EUR 645

HIV 1 Envelope gp41 Protein

abx060584-05mg 0.5 mg
EUR 940

HIV 1 Envelope gp41 Protein

abx060585-100ug 100 ug
EUR 1080

HIV-1 Envelope (233) Protein

20-abx260140
  • EUR 885.00
  • EUR 342.00
  • EUR 1372.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Recombinant HIV-1 gp 41 Envelope Protein

VAng-0532Lsx-inquire inquire Ask for price
Description: HIV type 1 Glycoprotein 41 Envelope Antigen, recombinant protein from E. coli, MW 146 kDa with Beta-galactosidase (114 kDa), 1.00 mg/mL.

Recombinant HIV-1 p24 gag, His Tag

7-07609 100µg Ask for price

Recombinant HIV-1 p24 gag, His Tag

7-07610 500µg Ask for price

Recombinant HIV-1 p24 gag, His Tag

7-07611 1000µg Ask for price

HIV-1 gp41, His tag

E410A25-10 10μg
EUR 694

HIV-1 p24, His tag

E410A26-20 20μg
EUR 434

Recombinant (E.Coli) HIV-1 Envelope conjugated to HIV-2 gp39

RP-564 100 ug
EUR 286

Recombinant (E.Coli) HIV Type-O Envelope

RP-565 100 ug
EUR 286

Recombinant HIV-2 gp36, His Tag

7-07738 100µg Ask for price

Recombinant HIV-2 gp36, His Tag

7-07739 500µg Ask for price

Recombinant HIV-2 gp36, His Tag

7-07740 1000µg Ask for price

HIV 2 Envelope Protein

abx060590-1mg 1 mg
EUR 1574

HIV-2 Envelope Protein

20-abx260147
  • EUR 885.00
  • EUR 342.00
  • EUR 1372.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Recombinant HIV-1 Envelope Protein, Untagged, E.coli-100ug

QP12241-100ug 100ug
EUR 218

Recombinant HIV-1 Envelope Protein, Untagged, E.coli-1mg

QP12241-1mg 1mg
EUR 1061

Recombinant HIV-1 Envelope Protein, Untagged, E.coli-500ug

QP12241-500ug 500ug
EUR 663

Recombinant (E.Coli, His-tag) HIV-1 pol Integrase

RP-555 10 ug
EUR 164

Recombinant (E.Coli, His-tag)HIV-1 p31 Integrase

RP-579 2 ug
EUR 164

Recombinant HIV-1 gp41, MBP tag

7-07630 100µg Ask for price

Recombinant HIV-1 gp41, MBP tag

7-07631 500µg Ask for price

Recombinant HIV-1 gp41, MBP tag

7-07632 1000µg Ask for price

HIV-1 Envelope conjugated to HIV-2 gp39 Protein

20-abx260144
  • EUR 885.00
  • EUR 342.00
  • EUR 1372.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Recombinant Zika Envelope Protein, His, E.coli-100ug

QP13997-HIS-100ug 100ug
EUR 218

Recombinant Zika Envelope Protein, His, E.coli-10ug

QP13997-HIS-10ug 10ug
EUR 201

Recombinant Zika Envelope Protein, His, E.coli-1mg

QP13997-HIS-1mg 1mg
EUR 1261

Recombinant Zika Envelope Protein, His, E.coli-2ug

QP13997-HIS-2ug 2ug
EUR 155

Recombinant Zika Envelope Protein, His, E.coli-500ug

QP13997-HIS-500ug 500ug
EUR 663

Recombinant Zika Envelope Protein, His, E.coli-50ug

QP13997-HIS-50ug 50ug
EUR 545

Recombinant HIV HTLV-1 Envelope Protein, Untagged, E.coli-100ug

QP12353-100ug 100ug
EUR 218

Recombinant HIV HTLV-1 Envelope Protein, Untagged, E.coli-1mg

QP12353-1mg 1mg
EUR 1061

Recombinant HIV HTLV-1 Envelope Protein, Untagged, E.coli-500ug

QP12353-500ug 500ug
EUR 663

Recombinant (E.Coli, His-tag) HIV-1 gp120 nef Mosaic

RP-534 100 ug
EUR 286

HIV type O envelope antigen

00178-V-01mg 0,1 mg
EUR 267.5
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence.

HIV type O envelope antigen

00178-V-1000ug 1000 ug
EUR 1282.5
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence.

HIV 2 gp36 envelope antigen

00180-V-01mg 0,1 mg
EUR 267.5
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36.

HIV 2 gp36 envelope antigen

00180-V-1000ug 1000 ug
EUR 1282.5
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36.

HIV 2 Envelope gp36 Protein

abx060591-1mg 1 mg
EUR 1358

HIV 2 Envelope gp36 Protein

abx060592-100ug 100 ug
EUR 1066

HIV Type-O Envelope Protein

20-abx260145
  • EUR 885.00
  • EUR 342.00
  • EUR 1372.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Recombinant HIV-2 gp36 Protein, His, E.coli-100ug

QP12269-HIS-100ug 100ug
EUR 201

Recombinant HIV-2 gp36 Protein, His, E.coli-1mg

QP12269-HIS-1mg 1mg
EUR 663

Recombinant HIV-2 gp36 Protein, His, E.coli-500ug

QP12269-HIS-500ug 500ug
EUR 463

Recombinant HIV-2 Envelope Protein, Untagged, E.coli-100ug

QP12267-100ug 100ug
EUR 218

Recombinant HIV-2 Envelope Protein, Untagged, E.coli-1mg

QP12267-1mg 1mg
EUR 1061

Recombinant HIV-2 Envelope Protein, Untagged, E.coli-500ug

QP12267-500ug 500ug
EUR 663

HCC-1 (CCL14) Human Recombinant Protein, His Tag

PROTQ16627-1 Regular: 10ug
EUR 317
Description: HCC-1 Human Recombinant fused with a 21 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 95 amino acids (20-93 a.a.) and having a molecular mass of 10.9kDa. The HCC-1 is purified by proprietary chromatographic techniques.

Recombinant (E.Coli) HIV-1 p24 >95% (no tag)

RP-536 10 ug
EUR 286

Recombinant HIV-2 gp36, MBP tag

7-07735 100µg Ask for price

Recombinant HIV-2 gp36, MBP tag

7-07736 500µg Ask for price

Recombinant HIV-2 gp36, MBP tag

7-07737 1000µg Ask for price

Envelope-1, Dengue Virus Subtype 1 Recombinant Protein, Insect Cells

PROTB1PNJ5-1 Regular: 10ug
EUR 317
Description: Recombinant Dengue Virus Subtype 1 produced in Insect Cells is a polypeptide chain containing amino acids 281-675 and having a molecular weight of approximately 50kDa. ;Dengue Envelope-1 is purified by proprietary chromatographic technique.

Human, LAG-1 (CCL4L1) Human Recombinant Protein, His Tag

PROTQ8NHW4-1 Regular: 20ug
EUR 317
Description: LAG-1 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 94 amino acids (24-92 a.a.) and having a molecular mass of 10.5kDa (Molecular weight on SDS-PAGE will appear higher).;LAG-1 is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

NRN1 Human, Neuritin-1 Human Recombinant Protein, His Tag

PROTQ9NPD7-1 Regular: 10ug
EUR 317
Description: Neuritin-1 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain (Ala28-Gly116) containing 99 amino acids including a 10 aa His tag at N-terminus. The total calculated molecular mass is 11.02kDa.

KLK1 Human, Kallikrein-1 Human Recombinant Protein, His Tag

PROTP06870-1 Regular: 10ug
EUR 317
Description: Kallikrein-1 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 259 amino acids (25-262) and having a molecular mass of 28.7kDa.;KLK1 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Recombinant HIV Type-O Envelope Protein, Untagged, E.coli-100ug

QP12237-100ug 100ug
EUR 218

Recombinant HIV Type-O Envelope Protein, Untagged, E.coli-1mg

QP12237-1mg 1mg
EUR 1061

Recombinant HIV Type-O Envelope Protein, Untagged, E.coli-500ug

QP12237-500ug 500ug
EUR 663

Visfatin Recombinant Protein Human, His Tag

PROTP43490-1 Regular: 25ug
EUR 317
Description: Visfatin Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 511 amino acids and having a molecular mass of 57 kDa. ;The recombinant human Visfatin is fused to His tag at N-Terminus.

TXN1, Thioredoxin Recombinant Protein, His Tag

PROTP0AA25-1 Regular: 10ug
EUR 317
Description: Recombinant Thioredoxin produced in E.Coli is a single, non-glycosylated polypeptide chain containing 119 amino acids (2-109 a.a.) and having a molecular mass of 12.9kDa. TRX contains an amino acid His Tag N-terminus and is purified by proprietary chromatographic techniques.

Streptavidin, Streptavidin Recombinant Protein, His Tag

PROTP22629-1 Regular: 20ug
EUR 317
Description: Recombinant Streptomyces Avidinii Streptavidin produced in E.Coli is a single, non-glycosylated polypeptide chain (25-183) containing a total of 167 amino acids and having a molecular mass of 17kDa. The Streptavidin protein is fused to an 8 aa N-terminal His-Tag and purified by proprietary chromatographic techniques.

C5a (His-Tag), murine recombinant protein

P1112-.1 100 µg
EUR 962
Description: Mouse complement C5a is a 77-amino acid peptide and is generated during complement activation from the ?-chain of complement C5. Its molecular mass is 9 kDa. Mouse C5a shares 60% and 82% amino acid sequence identity to human C5a and rat C5a, respectively

C5a (His-Tag), murine recombinant protein

P1112-1 1 mg
EUR 6940
Description: Mouse complement C5a is a 77-amino acid peptide and is generated during complement activation from the ?-chain of complement C5. Its molecular mass is 9 kDa. Mouse C5a shares 60% and 82% amino acid sequence identity to human C5a and rat C5a, respectively

HIV-1 Tat Protein Peptide

B1433-1 1 mg
EUR 128
Description: HIV-1 Tat Protein Peptide

IL-1-alpha Interleukin-1 alpha Mouse Recombinant Protein, His Tag

PROTP01582-1 Regular: 20ug
EUR 317
Description: IL 1 alpha Mouse Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 179 amino acids (115-270 a.a) and having a molecular mass of 20.4kDa.;IL 1 alpha is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

IL-1-alpha Interleukin-1 alpha Human Recombinant Protein, His Tag

PROTP01583-1 Regular: 20ug
EUR 317
Description: IL-1A Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 159 amino acids fragment (113-271) with an amino-terminal hexahistidine tag and having a total molecular mass of 22.5kDa. ;The Interleukin-1 alpha His-tag is purified by proprietary chromatographic techniques.

IL-1-beta Interleukin-1 beta Mouse Recombinant Protein, His Tag

PROTP10749-1 Regular: 25ug
EUR 317
Description: Interleukin-1 beta Mouse Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 189 amino acids and having a molecular mass of 21 kDa. ;The IL-1b is fused to His-Tag and purified by proprietary chromatographic techniques.

IL-1-alpha Interleukin-1 alpha Rat Recombinant Protein, His Tag

PROTP16598-1 Regular: 20ug
EUR 317
Description: IL 1 alpha Rat Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 179 amino acids (115-270 a.a) and having a molecular mass of 20.2kDa.

Recombinant HIV Type-O gp41, MBP tag

7-07720 100µg Ask for price

Recombinant HIV Type-O gp41, MBP tag

7-07721 500µg Ask for price

Amphibian pores and skin is a wealthy supply of protection peptides with antiviral exercise. Here, we characterised a lectin-like peptide, fejerlectin (RLCYMVLPCP), remoted from the pores and skin of the frog Fejervarya limnocharis. Fejerlectin confirmed important hemagglutination and d-(+)-galacturonic acid-binding actions. Furthermore, fejerlectin suppressed the early entry of HIV-1 into goal cells by binding to the N-terminal heptad repeat of HIV-1 gp41 and stopping 6-HB formation and Env-mediated membrane fusion. Fejerlectin is the smallest lectin-like peptide recognized to date and represents a new and promising platform for anti-HIV-1 drug growth.